A First-in-Class Drug Delivery System for NMIBC
- Inlexzo, also known as the gemcitabine intravesical system or TAR-200, introduces sustained intravesical release of gemcitabine for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), potentially overcoming the short dwell time limitations of standard instillation.
- The drug’s approval was based on Cohort 2 of the SunRISe-1 trial (NCT04640623). At any point during the trial, 82.4% of patients achieved a complete response, defined as no detectable cancer on cystoscopy or urine cytology, and about 50% of those responders maintained that response for at least 12 months.
- The approval adds another option to existing therapies like pembrolizumab, nadofaragene firadenovec, and nogapendekin alfa inbakicept, with selection driven by patient preference, comorbidities, and tolerance for intravesical procedures.
- Careful patient selection remains critical, despite promising data. “We do have to be cautious about patient selection because you may delay cystectomy in the wrong patients and that could lead to a catastrophic progression event,” Dr. David Aggen, a genitourinary medical oncologist at Memorial Sloan Kettering Cancer Center, tells SurvivorNet Connect.
In September 2025, the U.S. Food and Drug Administration approved Inlexzo (also known as the gemcitabine intravesical system or TAR-200) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The approval was granted under Priority Review and supported by a Breakthrough Therapy Designation. It’s the first intravesical drug-releasing device approved for bladder cancer and may give patients the opportunity to put off surgery or forego it altogether.
What differentiates TAR-200 is not the agent itself, but the delivery. Rather than standard intravesical instillation, which is limited by short dwell time, TAR-200 provides sustained intravesical release of gemcitabine over several weeks, potentially increasing tumor exposure to the drug.
“The value of TAR-200 is that it delivers gemcitabine slowly over the course of weeks,” Dr. David Aggen, a genitourinary medical oncologist at Memorial Sloan Kettering Cancer Center, tells SurvivorNet Connect. “We think the sustained exposure of gemcitabine may result in more drug exposure ultimately to the cancer and that you may have better outcomes. That’s the particular advantage.”
Yet despite TAR-200’s promising performance in trials, careful patient selection is still critical.
Interpreting Strong Data
The FDA’s approval was based on Cohort 2 of the SunRISe-1 trial (NCT04640623), a multicenter, single-arm study that enrolled 85 patients with BCG-unresponsive NMIBC with carcinoma in situ.
“The approval was based on a complete response rate of 82%, with a median duration of response of about 25.8 months,” Dr. Aggen says.
Key findings include:
- At any point during the trial, 82.4% of patients achieved a complete response, defined as no detectable cancer on cystoscopy or urine cytology.
- Approximately 51% of responders maintained that response for at least 12 months.
For context, pembrolizumab achieved a complete response rate of approximately 41% in its pivotal trial. Nadofaragene firadenovec reached 51%, while nogapendekin alfa inbakicept plus BCG demonstrated a 62% complete response rate.
While TAR-200’s 82% response rate represents the highest reported single-agent activity in this setting, these cross-trial comparisons should be interpreted cautiously given differences in study design and patient populations.
“Where bladder preservation is a goal for many patients, the prospect of being able to keep your bladder intact and remaining disease-free, about a 50% chance, is pretty good,” Dr. Aggen says.
Longer-term durability beyond one year remains an area of ongoing follow-up.
Managing Side Effects
The safety profile from SunRISe-1 was consistent with intravesical therapy.
The most common adverse events were lower urinary tract symptoms, such as:
- Frequent urination (43.5%)
- Dysuria (40%)
- Urinary urgency (24.7%)
- Urinary tract infections (21.2%)
These events were predominantly low-grade and resolved after a median of about three weeks.
“An advantage of intravesical therapies is that the drug is delivered locally and you don’t have that risk of longer-term permanent toxicities,” Dr. Aggen says. “Generally, the toxicities within intravesical therapies are really limited to the time patients are receiving the therapy and those aren’t systemic toxicities.”
This contrasts with systemic immunotherapy such as pembrolizumab, where immune-related adverse events may persist beyond treatment.
Where TAR-200 Fits In A Crowded Landscape
TAR-200 enters a rapidly evolving space with multiple bladder-preserving options for BCG-unresponsive disease. In the absence of head-to-head data, treatment selection is increasingly individualized, driven by patient comorbidities, tolerance for systemic therapy, logistical considerations, and preferences around intravesical procedures.
For some patients, the appeal of TAR-200 lies in its localized mechanism and avoidance of systemic exposure. For others, the requirement for repeated device placement every three weeks during the induction phase may be a limiting factor.
More broadly, TAR-200 represents not just another agent, but a distinct drug delivery platform, introducing sustained intravesical therapy as a potentially important strategy in this disease setting.
Who Is The Right Patient?
Despite encouraging efficacy, careful patient selection remains critical.
“Inlexzo [TAR-200] is a favorable option for patients who have BCG-unresponsive disease,” Dr. Aggen notes. “I think that patients need to have a component of carcinoma in situ. Patients that have pure T1 disease that’s refractory to BCG are a much higher risk group, and perhaps those are patients who should be sent to their urologist for a discussion of an early cystectomy.”
Another challenge with TAR-200 is how frequently patients will need to come in for device installation.
“You need a patient who’s willing and agreeable to go through those procedures,” Dr. Aggen adds.
Beyond logistics, the risk of delaying definitive surgery must be weighed carefully. Approximately 8% of patients in SunRISe-1 progressed to muscle-invasive disease.
“We do have to be cautious about patient selection because you may delay cystectomy in the wrong patients and that could lead to a catastrophic progression event,” Dr. Aggen adds.
His advice is to maintain structured surveillance. TAR-200 introduces a novel intravesical drug delivery strategy with a strong efficacy signal in a high-risk population.
As longer-term data mature and additional therapies emerge, the key challenge will be determining how best to sequence these options, and which patients are most likely to benefit from each approach.
